Clinical Trials Logo
  1. Home
  2. Nasopharyngeal Cancer
  3. NCT03003182
  4. Details
NCT03003182 Clinical Trial

A Study of Nasopharyngeal Carcinoma From Guangdong

Nasopharyngeal Cancer Clinical Trial

Official title:
A Prospective Cohort Study of Nasopharyngeal Carcinoma to Establish Prognostic Models, to Discover Toxicity Associated Predictors and to Validate Randomized Trials in Clinical Practice

Clinical Trial Details — Status: Recruiting

Administrative data
NCT number NCT03003182
Other study ID # 2016-FXY-098-Dept. of RT
Secondary ID
Status Recruiting
Phase N/A
First received December 18, 2016
Last updated June 13, 2017
Start date May 10, 2017
Est. completion date May 2021

Study information
Verified date June 2017
Source Sun Yat-sen University
Contact Fang-Yun Xie, MD
Phone +86-02087342618
Email xiefy@sysucc.org.cn
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

This prospective cohort study aims to establish prognostic models, to discover toxicity associated predictors and to validate randomized trials in clinical practice.

Recruitment information / eligibility
Status Recruiting
Enrollment 2000
Est. completion date May 2021
Est. primary completion date May 2019
Accepts healthy volunteers No
Gender All
Age group N/A and older
Eligibility Inclusion Criteria:

- histological confirmed nasopharyngeal carcinoma;

- scanned by magnetic resonance imaging from calvaria vertex to clavicles before treatment;

- pretreatment Epstein-Barr virus deoxyribonucleic acid copy number is available;

- irradiated with intensity-modulated radiotherapy;

Exclusion Criteria:

- finishing anticancer therapy in two or more hospitals;

- pregnancy or lactation;

- diagnosed with other sort of cancer before or during the treatment.

Study Design

Related Conditions & MeSH terms

Locations
Country Name City State
China Sun Yat-sen University Cancer Center Guangzhou Guangdong

Sponsors (1)
Lead Sponsor Collaborator
Sun Yat-sen University

Country where clinical trial is conducted

China, 

Outcome
Type Measure Description Time frame Safety issue
Primary overall survival 3-years
Secondary Number of participants with treatment-related acute adverse events as assessed by CTCAE v4.0 30-days
See also
  Status Clinical Trial Phase
Completed NCT00370890 - A Trial of Adjuvant Chemotherapy in Nasopharyngeal Carcinoma Patients With Residual Epstein-Barr Virus (EBV) DNA Following Radiotherapy Phase 3
Recruiting NCT04340024 - Discovery of Biomarkers for Intrinsic Radiation Sensitivity in Cancer Patients
Completed NCT00697619 - To Evaluate the Efficacy of ZOMETA® in Treatment of Bone Metastases in Patients With Stage IV Nasopharyngeal Cancer Phase 2
Completed NCT00078546 - EBV-Specific CTLs Following CD45 Antibody to Patients With Epstein-Barr Virus (EBV) + Nasopharyngeal Carcinoma (NPC) Phase 1
Recruiting NCT04453826 - Concurrent and Adjuvant PD1 Treatment Combined With Chemo-radiotherapy for High-risk Nasopharyngeal Carcinoma Phase 3
Active, not recruiting NCT01074021 - Nimotuzumab in Combination With Chemoradiation for Nasopharyngeal Cancer Phase 3
Active, not recruiting NCT03890185 - Docetaxal & Cisplatin vs LDFRT + Docetaxal & Cisplatin in Locally Advanced NPC Phase 2
Not yet recruiting NCT04158414 - Applying PET/MR in Oncology - a Prospective Project N/A
Completed NCT02608073 - A Study of Capecitabine (Xeloda) as First-Line Chemotherapy in Participants With Metastatic Nasopharyngeal Cancer Phase 2
Completed NCT03656250 - Assessment of Treatment Response of Nasopharyngeal Cancer Using Simultaneous 18F-FDG-PET and MRI
Recruiting NCT02012699 - Integrated Cancer Repository for Cancer Research
Recruiting NCT04476641 - A Study of DC-CIK Immunotherapy in the Treatment of Solid Tumors Phase 2
Terminated NCT03144661 - An Open-Label Safety and Tolerability Study of INCB062079 in Subjects With Advanced Hepatocellular Carcinoma and Other Malignancies Phase 1
Not yet recruiting NCT06414577 - Irinotecan Liposomes in Combination With Nituzumab for the Treatment of Recurrent/Metastatic Nasopharyngeal Carcinoma After Failure of First-Line or Higher Immunotherapy Phase 2
Not yet recruiting NCT06349889 - Adebrelimab and Chemoradiotherapy in High-risk Locoregionally Advanced Nasopharyngeal Carcinoma Phase 2
Completed NCT01094405 - Efficacy of Recombinant Epstein-Barr Virus (EBV) Vaccine in Patients With Nasopharyngeal Cancer Who Had Residual EBV DNA Load After Conventional Therapy Phase 2
Not yet recruiting NCT05305131 - Phase II Randomised Trial of Induction Gemcitabine and Cisplatin Versus Gemcitabine, Cisplatin, Pembrolizumab and Bevacizumab (GPPB) in Nasopharyngeal Cancer Phase 2
Completed NCT01800071 - A Phase Ib Trial of MVA-EBNA1/LMP2 Vaccine in Nasopharyngeal Carcinoma Phase 1
Recruiting NCT00304694 - Whole-Body 18F-FDG PET in Induction Chemotherapeutic Response for Advanced NPC Patients N/A
Recruiting NCT05638269 - A Multicentre Study on Features of the Gut Microbiota of Patients With Critical Chronic Diseases in China